Gabapentin for Pre-Visit Feline Anxiety: Evidence and Clinical Use

Bottom line

• In a blinded randomized crossover trial of 20 cats, owner-assessed stress scores during transportation and veterinary examination were significantly lower after a single pre-appointment oral dose of gabapentin than after placebo, and veterinarian-assessed compliance improved [1].
• Transient sedation is the dominant adverse effect: approximately 40% of cats were ataxic or wobbly at the examination, and all side effects resolved within about 8 hours of administration — a timeline that directly drives dosing and client counseling [1].
• A 2025 systematic review of 20 studies concluded gabapentin produces mild-to-moderate anxiolytic, sedative, and analgesic effects in cats without adverse cardiovascular, echocardiographic, or hemodynamic consequences [2].
• Evidence for gabapentin in cats extends beyond anxiolysis: a 2025 blinded, placebo-controlled study found gabapentin reduced dermatitis lesion scores across all treatment arms in feline atopic skin syndrome (FASS), and ciclosporin required the addition of gabapentin to reach statistical significance [4].
• Gabapentin is used off-label for feline anxiolysis and dermatologic adjunct use; there is no FDA veterinary label for either indication.

Drug facts

• Class: Alpha-2-delta calcium channel ligand (anticonvulsant / analgesic / anxiolytic).
• Mechanism: Binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing presynaptic calcium influx and excitatory neurotransmitter release. Its anxiolytic mechanism in cats is not fully elucidated, but the same central action is invoked to explain its effect on pruritus — dampening central amplification of peripheral itch signals analogous to its role in neuropathic pain [4].
• Route: Oral (capsule or compounded liquid). Administration mixed with wet or dry food is feasible and well tolerated [2]. No FDA-approved feline formulation exists; use is per-prescriber direction.
• Indication: Off-label anxiolytic/sedative for feline pre-visit stress reduction; investigational adjunct in FASS. FDA-approved in humans for epilepsy and postherpetic neuralgia.
• Approval: No FDA veterinary label for feline anxiety or dermatology; used off-label under veterinary supervision.
• Contraindications / cautions: No veterinary label. Use with caution in cats with renal impairment, as gabapentin is eliminated renally and clearance may be reduced.
• Common AEs (human label, observed in cats): Sedation, ataxia, lethargy [1][2].

Does it work? Efficacy for pre-visit anxiolysis

The pivotal evidence is the blinded, randomized crossover clinical trial by van Haaften et al. (2017), enrolling 20 healthy cats with a documented history of stress or fractious behavior during veterinary visits. Each cat attended two visits one week apart, receiving gabapentin or a placebo capsule in counterbalanced order. Owner-assessed stress scores during both transportation and veterinary examination were significantly lower on gabapentin than on placebo, and veterinarian-assessed compliance scores were also significantly improved [1]. The crossover design is a particular strength, because each cat serves as its own control and inter-individual variability in baseline fearfulness is removed from the comparison.

The 2025 systematic review by Laguardia et al. (Veterinary Sciences), which screened 543 records and analyzed 20 studies, reinforced this signal: as of 2025, gabapentin mildly to moderately reduces anxiety in cats, with responsiveness that may vary by dose, alongside positive behavioral, analgesic, and sedative effects [2]. Importantly, the review found the benefit is not merely a by-product of sedation — behavioral and analgesic improvements were distinct from any cardiovascular or autonomic suppression [2].

How does it compare? Gabapentin vs pregabalin

A separate 2025 systematic review (Miranda-Cortés et al., Animals) compared the anxiolytic and analgesic profiles of gabapentin and pregabalin in cats. As of 2025, both agents reduce anxiety and pain, and the review supports the use of either drug [3]. The two evidence bases are not symmetric, and this is where clinicians should weigh the trade-off explicitly:

• The case for gabapentin rests on the larger published evidence base for pre-visit anxiolysis, anchored by the van Haaften randomized crossover trial [1] and corroborated by the Laguardia systematic review [2].
• The case for pregabalin rests on a potentially more favorable pharmacokinetic profile, positioning it as an emerging alternative [3].

Neutral synthesis: the Miranda-Cortés review did not establish superiority of either agent and explicitly noted that head-to-head randomized clinical trials in cats are lacking [3]. For a vet choosing today, gabapentin remains the better-evidenced default for pre-visit stress, with pregabalin a reasonable alternative where its PK profile is advantageous — but neither can yet claim a comparative efficacy edge from controlled feline data.

Is it safe? Adverse effects and cardiovascular profile

Sedation and ataxia are the characteristic adverse effects, and the van Haaften trial quantifies them: approximately 40% of gabapentin-treated cats were wobbly or ataxic at the time of examination, consistent with central nervous system sedation, and all side effects resolved within about 8 hours of administration [1]. The Laguardia systematic review characterizes this sedation as mild to moderate and self-resolving, and confirms an overall positive behavioral safety profile [2].

On cardiovascular safety the evidence is reassuring: as of 2025, the systematic review found gabapentin does not negatively alter cardiovascular, echocardiographic, or hemodynamic parameters in cats [2]. This distinguishes gabapentin's mechanism of stress reduction from agents that lower measured stress via cardiovascular or autonomic depression.

The ~40% ataxia rate and the 8-hour resolution window are concrete parameters for client preparation. A cat dosed in the morning for a mid-day appointment should be expected to show residual sedation during the visit — this is anticipated and does not require intervention — but owners should be counseled to keep treated cats indoors and away from high surfaces (furniture, stairs) throughout the effect window [1].

Beyond anxiolysis: gabapentin as a dermatologic adjunct in FASS

A 2025 prospective, blinded, placebo-controlled study by Morency et al. (Veterinary Dermatology) in 26 cats with naturally acquired feline atopic skin syndrome broadens the feline evidence for gabapentin into dermatology. Cats received prednisolone, ciclosporin, or placebo daily for 5 weeks, after which gabapentin was added at the published protocol dose for a further 3 weeks; the Feline Dermatitis Extent and Severity Index (FeDESI) was scored at baseline and weeks 2, 4, and 7 [4].

Key results, as of 2025:

• Gabapentin decreased FeDESI across all treatment groups (P < 0.001), with the highest incidence rate ratio (2.59) versus placebo [4].
• Prednisolone alone produced a significant FeDESI improvement, whereas ciclosporin required the addition of gabapentin to reach significance (P < 0.034) [4].
• FeDESI improvements were associated with statistically significant decreases in actimetry-assessed motor activity, providing an objective correlate of reduced itch behavior rather than relying on scoring alone [4].

Mechanistically, the authors frame the effect as central sensitization: gabapentin's block of alpha-2-delta calcium channels reduces central amplification of peripheral itch signals, a pathway distinct from the peripheral immunologic mechanisms of ciclosporin or corticosteroids [4]. The differential finding — ciclosporin needing gabapentin while prednisolone did not — may reflect differences in onset speed between the immunosuppressants or a ceiling effect in ciclosporin's peripheral action that makes central adjunctive treatment more impactful [4].

Interpret with appropriate caution: the study was conducted in a laboratory colony, which limits generalizability to diverse client-owned populations, though the controlled design and objective actimetry strengthen the causal interpretation [4]. Regulatory context: the Atopica for Cats (cyclosporine oral solution, Elanco) label confirms ciclosporin is approved for the feline allergic dermatitis spectrum that includes FASS manifestations [5]. Gabapentin's role here remains investigational and off-label — but for a clinician already using gabapentin for stress reduction in an atopic cat, these data are a reason to consider whether a dermatologic benefit accompanies that use.

Contraindications, precautions & PK

• No veterinary label. All feline use is off-label; there are no FDA-approved feline formulations, dosing, or contraindication statements. Consult current species-specific formularies for dosing.
• Renal elimination. Gabapentin is cleared renally. Confirm adequate renal function before initiating gabapentin in cats with suspected or known chronic kidney disease, in whom reduced clearance can prolong and intensify sedation.
• Onset and duration. Owner-reported peak effect in the van Haaften crossover trial occurred approximately 2–3 hours after oral administration; sedation-related effects resolve within about 8 hours [1].
• Expected, self-limiting sedation. Ataxia in roughly 40% of cats is anticipated, mild-to-moderate, and self-resolving; it is not an indication to intervene, but it does warrant environmental precautions during the effect window [1][2].

Practical decision support

• Timing. Administer approximately 2–3 hours before the scheduled visit to align peak effect with transport and examination [1].
• Client counseling. Warn owners that a wobbly gait is common, expected, and self-resolving; instruct them to keep the cat indoors and away from high surfaces until the ~8-hour window passes [1].
• During the visit. Residual sedation in a morning-dosed cat presenting mid-day is expected and requires no intervention [1].
• Patient selection. Screen renal function before use in cats with known or suspected CKD; individualize dose and monitor for residual post-visit sedation [1][2].
• Choosing the agent. Prefer gabapentin as the better-evidenced default for pre-visit anxiolysis; consider pregabalin where its PK profile is advantageous, recognizing no controlled head-to-head feline data exist [3].
• Dermatology overlap. In an atopic cat already on gabapentin for stress, be aware of the emerging FASS adjunct signal — particularly alongside ciclosporin — while treating it as investigational and off-label [4][5].

Frequently Asked Questions

Is gabapentin approved by the FDA for feline anxiety? No. Gabapentin is used off-label for feline pre-visit anxiety. There is no FDA-approved veterinary label for this indication; consult a licensed veterinarian for guidance.

How quickly does gabapentin take effect in cats? Owner-reported peak effect in the van Haaften 2017 crossover trial occurred approximately 2 to 3 hours after oral administration [1].

How often do cats get wobbly after gabapentin, and how long does it last? In the van Haaften 2017 trial, approximately 40% of gabapentin-treated cats showed ataxia or wobbliness at the examination, and all side effects resolved within about 8 hours of administration [1].

Does gabapentin affect a cat's heart or blood pressure? As of 2025, a systematic review found gabapentin does not negatively alter cardiovascular, echocardiographic, or hemodynamic parameters in cats [2].

Can gabapentin be given with food? Yes. The 2025 systematic review confirmed oral administration mixed with wet or dry food is feasible and well tolerated [2].

How does gabapentin compare to pregabalin for feline anxiety? As of 2025, a systematic review found both reduce feline anxiety and pain and supports the use of either. Gabapentin has the larger published evidence base for pre-visit use; pregabalin may offer pharmacokinetic advantages but lacks equivalent randomized trial data in cats, and no head-to-head feline trials exist [3].

What should clients be told about gabapentin sedation? Tell owners that a mild wobbly gait is common, expected, and self-resolving. Keep the cat indoors and away from high surfaces during the effect window, which typically resolves within about 8 hours [1].

Does gabapentin have a role in feline atopic skin syndrome? A 2025 blinded, placebo-controlled study found gabapentin reduced FeDESI lesion scores across all treatment groups (highest incidence rate ratio 2.59 vs placebo), with ciclosporin requiring gabapentin to reach significance — suggesting a central sensitization component to feline pruritus. Use for FASS remains investigational and off-label [4].

Changelog

• 2026-06-06: First published.
• 2026-07-06: Consolidated hub. Folded in the June 15, 2026 dispatch (quantified ~40% sedation/ataxia rate and 8-hour resolution window from van Haaften 2017, with client-counseling implications) and the June 8, 2026 dispatch (Morency 2025 Vet Dermatol RCT on gabapentin + prednisolone/ciclosporin in FASS, plus the Atopica for Cats regulatory context). Corrected the gabapentin-vs-pregabalin systematic review journal attribution to Animals (Basel) (Miranda-Cortés et al. 2025) to match the resolved source.